Learning Objectives
- Describe the general principles of cytotoxic antineoplastic drug action and relate these to their adverse effects
- Describe the cellular MoA of the major classes of cytotoxic antineoplastic drugs: antimetabolites, alkylating agents, platinum compounds, vinca alkaloids, taxanes, topoisomerase inhibitors, podophyllotoxins, anthracyclines, and PARP inhibitors, and relate to their cell cycle specificity
- Outline the key adverse effects of these cytotoxic antineoplastic drugs classes & major mechanisms responsible for CINV
- Describe the MoA of anti-androgens, aromatase inhibitors, GnRH analogues and SERMs and relate to their therapeutic use for different hormone-sensitive cancers
- Describe the MoA and major adverse effects of tyrosine kinase inhibitors and mTOR inhibitors, and relate MoA to alterations in TK signalling various cancers
- Describe the MoA of the 3 main groups of antineoplastic antibodies (CD Abs, GF receptor Abs, both checkpoint inhibitors) and outline their major adverse effects
- Outline the major mechanisms responsible for resistance to antineoplastic drugs
Cancer Chemotherapy
- what are the 3 main modalities for treating cancer?
- compare intrinsic vs acquired antineoplastic drug resistance?
- what are some mechanisms of antineoplastic drug resistance?
- what is the mechanism of CINV?
- how is CINV treated?
Cytotoxic Antineoplastic Drugs
- generally, what do cytotoxic antineoplastic drugs do?
- what don’t cytotoxic drugs do to cancer?
- name all of the cytotoxic antineoplastic drug classes?
- Cell Cycle Stage Sensitive to Drugs